SynthesisActa dermato-venereologica2020
A Systematic Review of Drug-Induced Pemphigoid.
Synthesis in Acta dermato-venereologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.
- Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment.Frontiers in immunology · 2024Pooled it
- The Immunological Intersection of Psoriasis and Autoimmune Diseases: Shared Pathways and Clinical Implications.Life (Basel, Switzerland) · 2026Review
- Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.Drugs · 2026Review
- Venetoclax-associated bullous dermatitis: A BCL-2 inhibitor-linked autoimmune blistering disease.JAAD case reports · 2026Article
- Dupilumab for Treatment-refractory Bullous Pemphigoid: A Case Series of Six Patients.Acta dermato-venereologica · 2026Article
- Recurrent Bullous Pemphigoid: A Case Report.Cureus · 2026Article
- A Multicenter Analysis of Patients with Bullous Pemphigoid: Clinical Characteristics and Insights into Drug-Associated Disease.International journal of molecular sciences · 2026Article
- Bullous Pemphigoid Mimicking Infection in a Diabetic Foot: A Diagnostic Challenge.Plastic and reconstructive surgery. Global open · 2026Article
- The Role of Anti-BP180 Antibody Monitoring in Bullous Pemphigoid: An Italian Single-Center Experience.Dermatology practical & conceptual · 2026Article
- Vedolizumab-induced Bullous Pemphigoid: A Case Report with Serological Evidence and Mechanistic Insights.Acta dermato-venereologica · 2026Article
- Vildagliptin and its Association with Bullous Pemphigoid.Annals of African medicine · 2026Article
- Autoimmunity to Collagen XVII (BP180-Ag2) in Pemphigoid Associated With Parkinson's Disease.Case reports in dermatological medicine · 2026Article
- The cutaneous mirror: leveraging drug-induced skin phenotypes as early visual risk signals for systemic toxicity, a comprehensive review.Frontiers in drug safety and regulation · 2026Review
- Pemphigoid associated with quinolone antibiotics: a real-world pharmacovigilance study of the FDA adverse event reporting system and literature-based evidence.Frontiers in immunology · 2026Article
- Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).Frontiers in immunology · 2026Article
- A Case of Nivolumab-Induced Bullous Pemphigoid-Successfully Treated with Rituximab.Journal of community hospital internal medicine perspectives · 2026Article
- Dupilumab for Drug-Induced Bullous Pemphigoid: A Case Series and Literature Review.Clinical, cosmetic and investigational dermatology · 2026Article
- A case of bullous pemphigoid in an ulcerative colitis patient treated with vedolizumab.JAAD case reports · 2025Article
- Association Between DPPs-4 Inhibitors and Bullous Pemphigoid: Reporting Odds Ratio Analysis Using EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development.International journal of dermatology · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid is an autoimmune subepithelial disease characterised by pruritus followed by urticarial plaques and finally bullae on the skin and mucosa. Drug-associated bullous pemphigoid (DABP) is a term used to describe instances of bullous pemphigoid demonstrating clinical, histological, or immunopathological features identical or similar to those of the idiopathic form of bullous pemphigoid, associated with the systemic ingestion, or topical application of particular drugs. In this study, we conducted a comprehensive search of the literature according to PRISMA guidelines and a total of 170 publications were included in the final qualitative analysis. In conclusion, 89 drugs were implicated in DABP. The strongest evidence for DABP is seen with gliptins, PD-1/PD-L1 inhibitors, loop diuretics, penicillin and derivatives. An appreciation of the medications associated with bullous pemphigoid enables clinicians to identify potential cases of DABP earlier and cease the offending medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.